Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab extension study in patients with advanced malignant tumors
CTR20200083Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, sponsored by Hengrui Therapeutics. Started Jul 2019; status: active.
02
Drugs
camrelizumab
Beyond the preview
Go deeper on CTR20200083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200083.